SCHEMBL6433522

SCHEMBL6433522

CC(C)(C)OC(=O)C1CCC(NS(=O)(=O)c2ccc3c(Cl)cnc(Cl)c3c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 6/20 0.51
PLG P00747 2/20 0.42
PLAT P00750 1/20 0.42
LMNA P02545 3/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
STK25 O00506 1/20 0.38
BRAF P15056 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433517 1.00 PLAU (0.51) PLAUPLGPLATLMNAMAPK1
SCHEMBL6433745 0.87 PLAU (0.50) PLAUPLGPLATLMNAPDK1
SCHEMBL6433740 0.87 PLAU (0.50) PLAUPLGPLATLMNAPDK1
SCHEMBL6433826 0.87 PLAU (0.50) PLAUPLGPLATLMNAPDK1
SCHEMBL6436237 0.86 PLAU (0.51) PLAUPLATLMNASMN1; SMN2ALDH1A1
SCHEMBL6436244 0.86 PLAU (0.51) PLAUPLATLMNASMN1; SMN2ALDH1A1
SCHEMBL6433510 0.80 PLAU (0.70) PLAULMNAMAPK1SMN1; SMN2ALDH1A1
SCHEMBL6434472 0.78 PLAU (0.43) PLAUPLGPLAT
SCHEMBL6436992 0.78 PLAU (0.43) PLAUPLGPLAT
SCHEMBL6434806 0.77 PLAU (0.54) PLAUPLGPLATALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885PLAT 48/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885PLAT 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.